Sobi to share new clinical data and research at EULAR 2025
STOCKHOLM, May 28, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) will present new clinical data and research outcomes at the annual European Congress of Rheumatology (EULAR 2025) in Barcelona from the 11-14 June 2025. Research will include clinical trial outcomes on the efficacy and safety of Gamifant in the treatment of macrophage activating syndrome, updates on trial details of Vonjo investigating the potential treatment of VEXAS, and an analysis on the management of uncontrolled gout.
Sobi will host a symposium on the dermatologic, rheumatologic, and hematologic features of VEXAS syndrome during the congress. The symposium will be chaired by Dr Sophie Georgin-Lavialle MD, PhD from the French National Reference Centre for auto-inflammatory diseases and inflammatory amyloidosis. The symposium will be followed by a panel discussion and Q&A.
"We are delighted that our continued advancements in treating rare disease, including those suffering with the most debilitating rheumatology conditions will be presented at this year's EULAR conference. Sobi's presentations will provide insights and treatment options for those working with patients with rheumatological conditions, providing them with the most up-to-date clinical data and approaches," said Lydia Abad-Franch, MD, MBA, Head of Research, Development, and Medical Affairs (RDMA), and Chief Medical Officer at Sobi.
"With several poster and oral presentations and a longer form symposium, we are proud to be able to show how research and collaboration can advance clinical practice – and we look forward to meeting and connecting with colleagues in Barcelona," Lydia Abad-Franch concluded.
Key data to be presented at EULAR 2025
Gamifant (emapalumab)
Efficacy and Safety of emapalumab in Patients with Macrophage Activation Syndrome in Still's disease: Results from a Pooled Analysis of Two Prospective Trials
Speaker: Professor Fabrizio De Benedetti (principal investigator of the study)
Oral presentation
Session title: Clinical Abstract Session: Proceedings in Juvenile Idiopathic Arthritis
Session date: Thursday 12 June
Session time: 10:30 - 12:00 CEST
Presentation time: 10:48 - 10:57 CEST
Location: Room 6.1
Exposure-safety analysis from two clinical trials of emapalumab in patients with macrophage activation syndrome in Still's disease
Speaker: Professor Fabrizio De Benedetti (principal investigator of the study)
Poster presentation
Session title: Poster View VI
Session date: Friday 13 June
Session time: 12:00 – 13:30 CEST
Location: Poster Hall
NASP (formerly SEL-212)
Variations in uncontrolled gout between Rheumatologists and Nephrologists
Poster presentation
Session title: Poster View VIII
Session date: Friday 13 June
Session time: 10:15 - 11:45 CEST
Location: Poster Hall
Vonjo (pacritinib)
Development of a Consensus Definition of VEXAS Flare for Use in Clinical Research
Poster presentation
Session title: Poster View VII
Session date: Friday 13 June
Session time: 14 :45 - 15 :45 CEST
Location: Poster Hall
PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome
Poster tour
Session Title: Poster Tour II/ Clinical and Basic Poster Tours: Autoinflammatory Diseases including VEXAS
Session date: Saturday 14 June
Session time: 10:15 -11:45 CEST
Presentation time: 10:29 - 10:36 CEST (4 mins + 2 mins Q&A)
Location: Poster Tour II
Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI)
Poster tour
Session title: Poster Tour II/ Clinical and Basic Poster Tours: Autoinflammatory Diseases including VEXAS
Session date: Saturday 14 June
Session time: 10:15 - 11:45 CEST
Presentation time: 10:43 - 10:50 CEST (4 mins + 2 mins Q&A)
Location: Poster Tour II
Medical Symposium
An in-depth presentation on VEXAS syndrome: the dermatologic, rheumatologic, and hematologic features of the condition. Followed by a panel discussion and Q&A
Symposium title: Putting on your VEXAS goggles: Seeing what's in plain sight
Session date: Friday 13 June
Session time: 17:30 - 18:30 CEST
Location: Fira de Barcelona, Room B4
About Gamifant® (emapalumab)
Gamifant® (emapalumab) is indicated for the treatment of adult and paediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy.
About Macrophage activation syndrome (MAS)
Macrophage activation syndrome (MAS) is a potentially life-threatening complication of Still's disease characterised by interferon-gamma (IFNγ)–driven systemic hyperinflammation. More than one-third of patients inadequately respond to high-dose glucocorticoids. Emapalumab, an anti-IFNγ antibody, demonstrated efficacy and safety in a phase 2 pilot study in patients with MAS in Still's disease and an inadequate response to high-dose glucocorticoids.
About NASP, formerly SEL-212
NASP is a novel investigational medicine designed to reduce serum urate (SU) levels in people with uncontrolled gout, potentially reducing harmful tissue urate deposits which when left untreated can lead to debilitating gout flares and joint deformity. NASP is administered every 4-weeks as a sequential, two-component, infusion therapy consisting of tolerogenic nanoencapsulated sirolimus (NAS) which mitigates the formation of anti-drug antibodies (ADAs) and a uricase, pegadricase (P), which reduces serum uric acid. ADAs develop due to unwanted immune responses to biologic medicines, reducing their efficacy and tolerability, which remains an issue across multiple therapeutic modalities and disease states including uncontrolled gout.
About VONJO® (pacritinib)
VONJO is a kinase inhibitor that is indicated in the US for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L. This indication is approved under accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
About VEXAS
VEXAS syndrome is a disease that causes inflammatory and hematologic (blood) manifestations. The syndrome is caused by mutations in the UBA1 gene of blood cells and acquired later in life. The condition is not genetically inherited.
About Sobi
Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.
Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-to-share-new-clinical-data-and-research-at-eular-2025,c4156162
The following files are available for download:
https://mb.cision.com/Main/14266/4156162/3474231.pdf
Sobi share New clinical Data and Research at EULAR 2025
View original content:https://www.prnewswire.co.uk/news-releases/sobi-to-share-new-clinical-data-and-research-at-eular-2025-302466843.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox Sports
an hour ago
- Fox Sports
10 most expensive transfers in soccer history: Where does Florian Wirtz rank?
Liverpool made a splash on Friday when they signed German midfielder Florian Wirtz in a deal that could become the biggest ever in English Premier League history. Liverpool could pay up to $156 million once add-ons are achieved to German side Bayer Leverkusen, which would break the Premier League mark set by Chelsea signing Endo Fernandez from Benfica for $130.5 million. Wirtz played at Leverkusen for five seasons and helped the club win its first ever Bundesliga League title in 2023. Now, he'll join the defending champions of the EPL, as well as the list of the highest-paid soccer players in the world. What players have commanded deals similar to the record-breaking one Wirtz just received? Here's a look at the top 10 most expensive transfers in soccer history and how they played out: 10. Jack Grealish: $126.8 million Jack Grealish's $126.8 million transfer from Aston Villa to Manchester City looks much better now than it did at the start. After struggling mightily in his first season with the Sky Blues, Grealish was a key contributor during City's treble-winning 2022-23 campaign, tallying five goals and 11 assists in all competitions, up from six goals and four assists last season. Grealish's transfer fee is the most for an English player ever. 9. Antoine Griezmann: $129 million Barcelona activated Antoine Griezmann's $129 million buyout clause from Atletico Madrid in 2019. However, Griezmman's time in Barcelona didn't last long, as he returned to Atléti on loan in 2021 after two unsuccessful seasons at the Camp Nou. Atléti made the transfer permanent in 2022 by paying $21 million for Griezmann, $108 million less than what Barcelona paid for him two years prior. Griezmann contributed 35 goals and 17 assists in 102 appearances for Barcelona. 8. Enzo Fernandez: $130.5 million Coming off of winning the FIFA Young Player Award at the 2022 FIFA World Cup in Qatar, Enzo Fernandez secured a $130.5 million transfer from Benfica to Chelsea in January. While the 22-year-old wasn't able to turn Chelsea's season around, he was one of the few bright spots for the Blues during a season in which they finished 12th in the English Premier League. 7. Joao Felix: $137 million Joao Felix's $137 million move from Benfica to Atlético Madrid was historic for both clubs, as it was Benfica's biggest sale in club history and Atlético's biggest-ever transfer. Unfortunately, Felix hasn't made much history in Madrid outside his price tag. While the 2019 Golden Boy-winner helped Atléti lift its first La Liga trophy in seven years in 2021, injuries and disagreements with the club's legendary manager Diego Simeone have prevented him from living up to his price tag. Felix spent the second half of the 2022-23 campaign on loan at Chelsea, and spent the 2024-25 season on loan with the Italian club AC Milan. 6. Ousmane Dembele: $145 million When Ousmane Dembele was healthy, the $145 million transfer fee Barcelona paid to acquire him from Borussia Dortmund in 2017 looked completely justified, but injuries made the deal difficult to evaluate. Because while he won three La Liga titles and three domestic cups in six years at Barcelona, he was sidelined for the high and lows the clubs has experienced in that time. His final season at Barcelona was arguably his most impactful, as he contributed five goals and seven assists en route to a La Liga title. Dembele ultimately transferred to Paris Saint Germain in 2023, and has since had a resurgence, helping the team to two league titles and winning the UEFA Champions League trophy in 2025. 5. Philippe Coutinho: $145 million The fifth-most expensive transfer in soccer history is also one of the worst. Pegged as the perfect replacement for club legend Andres Iniesta, Philippe Coutinho transferred to Barcelona from Liverpool for a fee of $145 million in 2018. What followed was the nightmare scenario for Barcelona. Coutinho, Barcelona's most expensive player of all time, played only one full season for the club before he was loaned out to FC Bayern before the start of his third season. Coutinho returned to Barcelona for the 2020-21 season, but a season-ending knee injury limited him to just 14 appearances in all competitions. In January 2022, Coutinho transferred to Premier League club Aston Villa for $26 million. Coutinho ended his Barcelona career with 25 goals and 14 assists in 106 appearances with Barcelona. With Liverpool, he had 54 goals and 45 assists in 201 appearances. 4. Moises Caicedo: $146 million The Ecuador midfielder's move was previously the most expensive deal by a British club, with Chelsea buying him from Brighton in August 2023, before Liverpool purchased Florian Wirtz. Caicedo appeared in 38 matches for Chelsea this past season, helping the team keep 11 clean sheets while finishing fourth in the English Premier League. 3. Florian Wirtz: $156 million (if add-ons achieved) Wirtz is one of the brightest young stars in world soccer. As a 20-year-old, he had 11 goals and 11 assists in 32 matches as he helped Bayer Leverkusen win its first Bundesliga league title. He followed that up with a 10-goal, 12-assist season as Leverkusen finished second in the Bundesliga and also made it to the Knockout Stage of the UEFA Champions League. Because of the lofty price tag, Wirtz will have loads of pressure on him when he arrives at Liverpool and slots in next to Alexis Mac Allister and Ryan Gravenberch in The Reds' midfield. 2. Kylian Mbappe: $194 million In hindsight, $194 million feels like a steal for a player of Kylian Mbappe's caliber. Though the 24-year-old did not win the Champions League with Paris Saint-Germain, he brought a record five consecutive Ligue 1 titles and eight domestic cups to the club since joining them from Monaco in 2017. He was also named Ligue 1 Player of the Year four times as a PSG player. In March of 2023, Mbappe passed Edinson Cavani's to become PSG's all-time leading goalscorer, and he did it in 54 fewer games. After seven seasons with PSG, Mbappe transferred to Real Madrid. 1. Neymar: $239 million It was always going to be difficult for Neymar to live up to the $239 million price tag that PSG paid Barcelona for his talents in 2017, but injuries made it even harder for him to justify it. He wasn't able to bring PSG its Champions League victory. Still, he had an outstanding career with the club, recording 118 goals and 77 assists in 173 appearances, and winning 13 trophies in six years. FOLLOW Follow your favorites to personalize your FOX Sports experience Kylian Mbappe Paris SG Ligue 1 recommended Get more from FIFA Men's World Cup Follow your favorites to get information about games, news and more
San Francisco Chronicle
an hour ago
- San Francisco Chronicle
Florian Wirtz joins list of most expensive soccer signings in history
Florian Wirtz became one of the most expensive players in soccer history when the Germany playmaker joined Liverpool from Bayer Leverkusen on Friday for a fee of up to 116 million pounds ($156 million). Neymar: $262 million (222 million euros) Paris Saint-Germain shattered the world-record transfer fee by signing the Brazil superstar from Barcelona in August 2017. It was more than double the outlay of Manchester United to sign Paul Pogba from Juventus for $116 million a year earlier. It remains the record transfer fee. ___ Kylian Mbappé: $216 million (180 million euros) A few weeks after buying Neymar, PSG also secured a loan deal for Mbappé — then the rising star of French soccer playing for Monaco — that included the option to make the move permanent in 2018. PSG did so, making it an outlay of nearly $500 million on two players. ___ Flush with cash after selling Neymar a year earlier, Barcelona spent most of it in a deal to buy Brazil playmaker Coutinho from Liverpool for a Spanish record fee. ___ Moises Caicedo: $146 million (115 million pounds) The Ecuador midfielder's move was previously the most expensive deal by a British club, with Chelsea buying him from Brighton in August 2023. ___ João Félix: $140 million (126 million euros) Atletico Madrid triggered a buyout clause in Félix's contract to sign the Portugal forward from Benfica in August 2019. ___ Jude Bellingham: $139 million (128.5 million euros) The England star got his big move to Real Madrid from Borussia Dortmund in June 2023, for an initial up-front fee of 103 million euros plus add-ons linked to performance. ___ Antoine Griezmann: $134 million (120 million euros) Atletico could afford to sign Félix after selling France forward Griezmann to Barcelona for a similar fee a few weeks earlier. ___ Neymar: $98 million (90 million euros) Outside from Europe, the biggest transfer deal also involved Neymar when he joined Al Hilal, a team in the Saudi Pro League, from Paris Saint-Germain in August 2023. That came at the height of Saudi Arabia's push to sign high-end soccer talent to ignite the oil-rich state's domestic league. ___
Yahoo
2 hours ago
- Yahoo
Novo Nordisk's subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025
Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was published in The Lancet and presented at the American Diabetes Association (ADA) Scientific Sessions.1,2 Oral amycretin phase 1 data on the safety, tolerability and weight loss potential in people with overweight or obesity was also published in The Lancet.3 Findings from the clinical trials indicate amycretin appeared tolerable with a safety profile consistent with other GLP-1 and amylin receptor agonists.1,2,3 Bagsværd, Denmark, 20 June 2025 – Novo Nordisk announces subcutaneous amycretin data being presented at the American Diabetes Association (ADA) 85th Scientific Sessions in Chicago, US.1 Full results of two clinical trials evaluating the safety, tolerability and weight loss potential of subcutaneous and oral amycretin in people with overweight or obesity were published today in The Lancet medical journal.1,3 Amycretin is the first treatment that combines GLP-1 and amylin receptor agonism biology in a single molecule. The published and presented results from the once-weekly subcutaneous amycretin phase 1b/2a clinical trial showed that participants who received the treatment demonstrated significantly greater weight loss across the full range of doses investigated compared to placebo. Data being presented at ADA were collected from two parts of the trial; dose escalation (amycretin 60 mg), and dose escalation and maintenance (amycretin 20 mg, 5 mg and 1.25 mg).1,2 No plateauing in weight reduction was observed at the end of treatment (ranging from 20 to 36 weeks) with all tested doses, suggesting that a longer treatment duration may potentially contribute to additional weight loss.1,2 Estimated mean change in body weight from baseline with once-weekly subcutaneous (SC) amycretin: 1,2 * Dose Treatment % Weight change % Weight change duration (SC amycretin) (placebo) 60 mg 36 weeks -24.3% -1.1%20 mg** 36 weeks -22.0% 1.9%5 mg** 28 weeks -16.2% 2.3%1.25 mg** 20 weeks -9.7% 2.0% * If all people adhered to treatment i.e. if all people followed the planned dosing schedule for the full trial period without any treatment discontinuations.** Administered during a 12-week maintenance period. Once-weekly subcutaneous amycretin treatment escalated up to 60 mg appeared tolerable with a safety profile consistent with other GLP-1 and amylin receptor agonists.1,2 The number of treatment-emergent adverse events (TEAEs) increased in a dose-dependent manner, were mostly gastrointestinal, and were comparable to the rate and profile of TEAEs reported in early-phase studies of GLP-1 receptor, GLP-1 receptor/gastric inhibitory polypeptide (GIP) receptor, and amylin receptor agonists.1,2 The majority of TEAEs were mild to moderate in severity and resolved by the end of the study period.1,2 Of the participants who discontinued the trial, the majority were due to non-TEAE reasons.1,2 'As pioneers in obesity innovation, we are exploring multiple biological pathways to develop potentially transformative medicines that support the individual needs and preferences of people with obesity on their weight loss journey towards overall improved health,' said Martin Holst Lange, executive vice president for Development at Novo Nordisk. 'Amycretin is the first investigational treatment that combines GLP-1 and amylin receptor agonism biology in one molecule, working on distinct pathways and offering complementary effects on appetite control. The findings published and presented today are encouraging. We are excited to advance the clinical development of subcutaneous and oral amycretin into phase 3 to assess its potential as a therapeutic option for weight management.' The published once-daily oral amycretin phase 1 clinical trial data showed that participants receiving amycretin achieved greater weight loss compared to placebo.3 After 12 weeks of treatment with amycretin up to 50 mg and up to 2 times 50 mg, participants achieved a mean change in body weight of -10.4% and -13.1% respectively, compared to -1.2% with placebo.3 There were no apparent signs of weight loss plateauing within the 12 weeks of treatment in either of these amycretin-treated groups.3 Once-daily oral amycretin appeared to have an acceptable safety profile and was tolerable in all tested doses, with TEAEs in line with what was expected from targeting GLP-1 and amylin receptors.3 All reported TEAEs occurred in a dose-proportional manner, were mild to moderate in severity, and mostly gastrointestinal. No new safety signals appeared during the study.3 Based on the findings from the oral and subcutaneous amycretin trials, Novo Nordisk recently announced it will advance amycretin into phase 3 trials to further investigate the treatment as a potential new therapeutic option for weight management.4 About amycretinAmycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an efficacious and convenient treatment for adults with overweight or obesity and for adults with type 2 diabetes. Amycretin is developed for subcutaneous and oral administration. Oral amycretin Phase 1 trial - The trial evaluated the single-ascending dose and multiple ascending doses for oral amycretin, up to 2 times 50 mg, in 144 people with overweight or obesity, with a total treatment duration of up to 12 weeks. Subcutaneous amycretin Phase 1b/2a trial - The trial investigated the safety, tolerability, pharmacokinetics, and proof-of-concept of once-weekly subcutaneous amycretin in 125 people with overweight or obesity. The trial was a combined single ascending dose, multiple ascending dose and dose-response trial investigating three different maintenance doses with a total treatment duration of up to 36 weeks. About Novo NordiskNovo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 9289abmo@ Liz Skrbkova (US)+1 609 917 0632lzsk@ Investors: Jacob Martin Wiborg Rode+45 3075 5956jrde@ Ida Schaap Melvold +45 3077 5649 idmg@ Sina Meyer +45 3079 6656 azey@ Max Ung+45 3077 6414mxun@ Frederik Taylor Pitter +1 609 613 0568fptr@ _______________________References The Lancet: Dahl K, Toubro, S, Dey S, et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: Results of a randomised, controlled, phase 1b/2a study. Dahl, K, et al. (2025). Amycretin, a Novel, Unimolecular GLP-1 and Amylin Receptor Agonist: Results of a Phase 1b/2a Clinical Trial. Poster 2002-LB. American Diabetes Association (ADA) 85th Scientific Sessions, Chicago, US, June 20 – 23, 2025. The Lancet: Gasiorek A, Heydorn A, Gabery S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, randomised, placebo-controlled study. Novo Nordisk Company Announcement. Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development. Available at: Attachment PR250621-ADA-AmycretinError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
